Do all patients with head and neck cancer benefit from radiotherapy and concurrent cetuximab?

The Lancet Oncology

Volumn 11, Issue 4, 2010, Pages 312-313

  Eriksen, Jesper Grau ^a   Lassen, Pernille ^b   Overgaard, Jens ^b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

CANCER RADIOTHERAPY; CLINICAL TRIAL; HEAD AND NECK CANCER; HUMAN; KARNOFSKY PERFORMANCE STATUS; LETTER; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; WART VIRUS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MALE; NEOPLASM PROTEINS; PAPILLOMAVIRUS INFECTIONS; PATIENT SELECTION;

EID: 77950332087     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70035-8     Document Type: Letter

References (5)

1. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11:21-28.
2. Bernier J, Schneider D Cetuximab combined with radiotherapy: an alternative to chemo-radiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?. Eur J Cancer 2007, 43:35-45.
3. Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14.
4. INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck: results from the DAHANCA 5 study. J Clin Oncol 2009, 27:1992-1998.
5. Lassen P, Eriksen JG, Dutoit SH, et al. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol 2010, 94:30-35.